Literature DB >> 2555082

EDRF increases cyclic GMP in platelets during passage through the coronary vascular bed.

U Pohl1, R Busse.   

Abstract

It was investigated whether endothelium-derived relaxing factor (EDRF) increases cyclic GMP (cGMP) content in platelets passing through the coronary bed. Boluses of washed platelets from healthy human donors were injected into the aortic perfusion line of isolated, saline-perfused rabbit hearts under constant flow conditions (28 +/- 2 ml/min). The coronary effluent was collected over 5 seconds, and the cGMP content of platelets was determined by radioimmunoassay. Platelet cGMP amounted to 0.34 +/- 0.11 pmol/mg protein after passage through the unstimulated coronary bed. During stimulation with acetylcholine (1 microM), it increased to 1.6 +/- 0.5 pmol/mg (p less than 0.01; n = 14). Simultaneously, the platelet recovery (measured over 20 seconds after injection) was enhanced (by 45 +/- 11%; p less than 0.01) during endothelial stimulation with acetylcholine. Treatment with the EDRF inhibitor hemoglobin (6 microM) completely abolished the increase in platelet cGMP (p less than 0.01; n = 11) as well as the enhanced platelet recovery (n = 8). Inhibition of EDRF by hemoglobin reduced also the basal platelet cGMP content to 0.17 +/- 0.11 pmol/mg (p less than 0.01). The data indicate that basally released EDRF is able to increase cGMP in platelets during a single passage through the coronary bed. The enhanced recovery of platelets after EDRF stimulation, which coincides with an increase of platelet cGMP, suggests that EDRF plays an important role as inhibitor of platelet activation in the coronary circulation.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2555082     DOI: 10.1161/01.res.65.6.1798

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  7 in total

Review 1.  St Cyres lecture. Endothelium in control.

Authors:  A H Henderson
Journal:  Br Heart J       Date:  1991-03

2.  On-line measurement of nitric oxide release from organic nitrates in the intact coronary circulation.

Authors:  K Schrör; S Förster; I Woditsch
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-08       Impact factor: 3.000

3.  NG-nitro-L-arginine antagonizes endothelium-dependent dilator responses by inhibiting endothelium-derived relaxing factor release in the isolated rabbit heart.

Authors:  D Lamontagne; U Pohl; R Busse
Journal:  Pflugers Arch       Date:  1991-04       Impact factor: 3.657

Review 4.  Role of nitric oxide in progression and regression of atherosclerosis.

Authors:  J P Cooke
Journal:  West J Med       Date:  1996-05

Review 5.  Advances in diabetes for the millennium: diabetes and the endothelium.

Authors:  Paresh Dandona; Ahmad Aljada
Journal:  MedGenMed       Date:  2004-09-29

6.  In vitro inhibition by endothelins of thrombin-induced aggregation and Ca2+ mobilization in human platelets.

Authors:  C Astarie-Dequeker; L Iouzalen; M David-Dufilho; M A Devynck
Journal:  Br J Pharmacol       Date:  1992-08       Impact factor: 8.739

7.  Arterial size determines the enhancement of contractile responses after suppression of endothelium-derived relaxing factor formation.

Authors:  J Galle; J Bauersachs; E Bassenge; R Busse
Journal:  Pflugers Arch       Date:  1993-03       Impact factor: 3.657

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.